High expectations in pseudophakes fueling expansion in laser vision correction base

Article

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing, especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up a new class of patients to the benefits of laser vision correction.

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing, especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up a new class of patients to the benefits of laser vision correction, said Steven J. Dell, MD, at Refractive Surgery Subspecialty Day.

"If cataract surgery is now being considered refractive surgery, then cataract surgery with implantation of a premium IOL is hyper-refractive surgery," said Dr. Dell, director, refractive and corneal surgery, Texan Eye, Austin, TX. "Recipients of these lenses are less tolerant of misses in our refractive target than their younger, laser vision correction counterparts. This is because a low hyperopic result in a young phakic patient may still result in 20/15 vision, but is totally unacceptable in a pseudophake.

"If refractive errors occur in sphere and/or cylinder, there are a number of options for correcting them. However, laser vision correction is the most accurate," Dr. Dell said.

When a decision is made to proceed with a laser vision enhancement, surgeons need to consider whether to perform a customized ablation or a conventional procedure.

Dr. Dell suggested performing a wavefront-guided procedure in the eyes of patients who have received either a monofocal lens, accommodating lens (crystalens, eyeonics), apodized diffractive lens (AcrySof ReSTOR, Alcon Laboratories), or multifocal lens (Tecnis, Advanced Medical Optics), assuming the wavefront is capturable and the data make sense. However, he cautioned against a custom wavefront-guided enhancement in eyes in which the zonal refractive multifocal IOL (ReZoom, Advanced Medical Optics) is implanted.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.